Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Leukemia nurse practitioner Ilene Galinsky and physician Daniel DeAngelo
CAR T-cell therapy is a promising treatment for patients with many types of blood cancer, including leukemia. It is a highly-specialized therapy that involves genetically modifying a patient's own T cells to attack their cancer.
Learn more about CAR T-cell therapy.
CAR T-cell therapy is FDA-approved for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).
Patients are evaluated carefully to determine if this therapy is appropriate for them, and are cared for by a team experienced in CAR T-cell therapy.
In addition to the FDA-approved therapy, Dana-Farber Brigham Cancer Center also offers clinical trials evaluating CAR T-cell therapy for other types of leukemia,
as well as other blood cancers.
Key eligibility criteria include:
Children and young adults may also be evaluated at Dana-Farber/Boston Children's Cancer and Blood Disorders Center (Dana-Farber/Boston
Contact Information for CAR T-Cell Therapy
For more information about CAR T-cell therapy, please call 877-801-CART (2278).
Pediatric CAR T-Cell Therapy
Dana-Farber/Boston Children's is a certified treatment center for providing the recently FDA-approved CAR T-cell therapy called KYMRIAH® to patients who are up to 25 years old with second or later relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).